Johnson & Johnson Halts Phase 2 Study of Antiviral for Dengue Prevention

On October 4, 2024, Johnson & Johnson announced the discontinuation of their Phase 2 field study (NCT05201794) that was evaluating the efficacy of the antiviral candidate mosnodenvir in preventing dengue virus in adults aged 18-65 years. This decision comes as part of a strategic shift in the company’s research and development focus within their Communicable Diseases unit. The company confirmed that there were no safety concerns identified in the course of the study.

While the Phase 2 field study has been discontinued, the efficacy data will become available after the ongoing final data analyses are completed. Study investigators have been informed of the discontinuation, and all participants have completed the study according to the protocol. The participants will be informed of the results once they are finalized.

Mosnodenvir, previously known as JNJ-1802, had demonstrated safety and tolerability in earlier Phase 1 and Phase 2a clinical trials. In particular, the Phase 2a human challenge study revealed that the compound exhibited antiviral activity against dengue (specifically DENV-3) in humans when compared to a placebo.

Despite the discontinuation of this specific study, Johnson & Johnson remains committed to combating dengue by sharing the results of these studies with the medical community. The company’s broader Communicable Diseases program continues to tackle some of the most persistent health issues globally, such as tuberculosis, HIV, extraintestinal pathogenic E. coli (ExPEC), and neglected tropical diseases like leprosy. This ongoing effort aims to enhance lives and foster a healthier, safer world.

Johnson & Johnson is dedicated to healthcare innovation, striving to prevent, treat, and cure complex diseases. Their work spans across Innovative Medicine and MedTech, positioning them to pioneer advancements in healthcare solutions. Through their efforts, Johnson & Johnson aims to deliver critical breakthroughs and significantly impact global health.